Pyoderma gangrenosum - Pyoderma Gangrenozum
Pyoderma Gangrenozum (Pyoderma gangrenosum) kam uchraydigan, yallig'lanishli teri kasalligi bo'lib, unda og'riqli pustulalar yoki tugunlar asta-sekin o'sib boradigan yaraga aylanadi. pyoderma gangrenozum (pyoderma gangrenosum) yuqumli emas. Davolash kortikosteroidlar, siklosporin yoki turli monoklonal antikorlarni o'z ichiga olishi mumkin. Bu har qanday yoshdagi odamlarga ta'sir qilishi mumkin bo'lsa-da, u asosan 40 va 50 yoshdagi odamlarga ta'sir qiladi.
☆ Germaniyaning 2022 yilgi Stiftung Warentest natijalariga ko'ra, iste'molchilarning ModelDermdan qoniqish darajasi pullik teletibbiyot maslahatlariga qaraganda bir oz pastroq bo'lgan.
Yarali kolitli odamning oyog'ida.
References
Pyoderma gangrenosum - qizil yoki binafsharang qirralari bo'lgan og'riqli yaralarni keltirib chiqaradigan noyob teri kasalligi. Bu yallig'lanish kasalligi sifatida tasniflanadi va neytrofil dermatozlar deb ataladigan guruhga kiradi. Pyoderma gangrenosum sababi murakkab bo'lib, genetik moyil bo'lgan odamlarda tug'ma va adaptiv immunitet bilan bog'liq muammolarni o'z ichiga oladi. So'nggi paytlarda tadqiqotchilar kasallikning potentsial boshlang'ich nuqtasi sifatida soch follikulasiga e'tibor berishdi.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum juda og'riqli yaralarni keltirib chiqaradigan noyob teri kasalligi. Biz uning sababini to'liq tushunmasak-da, bu ma'lum immunitet hujayralarining faolligini oshirishni bilamiz. Kasallikni davolash hali ham oson emas. Bizda immunitet tizimini bostiradigan yoki uning faoliyatini o'zgartiradigan turli xil dorilar mavjud. Ular bilan bir qatorda, biz jarohatlarni davolash va og'riqni boshqarishga ham e'tibor qaratamiz. Kortikosteroidlar va siklosporin ko'pincha davolash uchun birinchi tanlovdir, ammo so'nggi paytlarda TNF-a inhibitörleri kabi biologik terapiyadan foydalanish bo'yicha ko'proq tadqiqotlar olib borilmoqda. Ushbu biologik preparatlar, ayniqsa, boshqa yallig'lanish kasalliklari bo'lgan bemorlarda ko'proq afzallik beriladi va ular kasallik jarayonida ilgari qo'llaniladi.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
